—
C+
C+ The full Closelook — membership. Open the C+ overview

Maravai Lifesciences Holdings Inc (MRVI) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Maravai Lifesciences Holdings Inc

MRVI in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Maravai LifeSciences supplies materials that let drugmakers develop new therapies, vaccines, cell and gene treatments, and diagnostics, through two segments, TriLink and Cygnus. TriLink manufactures nucleic acids, messenger RNA, oligonucleotides and CleanCap capping chemistry used in gene therapy and vaccine production. Cygnus makes analytical kits that detect impurities during biologic manufacturing. Its customers are biopharmaceutical companies, academic research institutions and diagnostics firms, and it is headquartered in San Diego.
Where it sits in the stack
Maravai has no seat in Rubin or Halo, our AI build-out indices; it sits instead in the life-sciences tools sleeve of our wider universe, supplying reagents and nucleic-acid building blocks used in biologic and gene-therapy manufacturing rather than any layer of the compute stack.
Who it is priced against
The diary's peer group carries no listed comparators for this name; a well-known public name working in similar nucleic-acid and bioprocess reagent supply is Thermo Fisher Scientific.
Why Closelook tracks it
It carries no Closelook score and holds no seat in Rubin or Halo; its only recorded index membership is the Russell 1000, and the diary has not quoted or scored it so far.
What the diary watches
The diary watches whether demand from vaccine and gene-therapy developers for nucleic-acid and CleanCap-based building blocks recovers, since that demand feeds the TriLink segment directly.

Maravai Lifesciences Holdings Inc (MRVI) trades on US exchanges.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for MRVI, from the same nightly bakes the boards use. Research diary readings, not advice.

Who it is priced against Biotechnology · United States · 8 names with week and year-to-date

Peer group

Biotechnology · United States

This name carries no Closelook score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against MRVI on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 50/100 · S&P 500 fund at 49, above its 50- and 200-day averagesEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-18
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 97th percentile of the window, +4.9% over 20 sessions. Factor regime → 2026-09-18
  • Sovereign pressure Index 0.07 · down 0.41 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-18

FAQ · from the current data · as of 2026-09-19

Quick answers

What is Maravai Lifesciences Holdings Inc (MRVI)?

Maravai Lifesciences Holdings Inc trades as MRVI on the US exchange (United States) in the Closelook research universe, as of the registry build of 2026-09-19.

Is MRVI in a Closelook index?

Not currently — Maravai Lifesciences Holdings Inc is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-19.

Where does MRVI trade against its moving averages?

Uptrend stack intact: Trades +0.5% vs the 50-day and +49.8% vs the 200-day average, 26% below the 52-week high and +173.9% off the 52-week low. Computed from daily closes. As of 2026-09-18 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does Maravai Lifesciences Holdings Inc do?

Maravai LifeSciences supplies materials that let drugmakers develop new therapies, vaccines, cell and gene treatments, and diagnostics, through two segments, TriLink and Cygnus. TriLink manufactures nucleic acids, messenger RNA, oligonucleotides and CleanCap capping chemistry used in gene therapy and vaccine production. Cygnus makes analytical kits that detect impurities during biologic manufacturing. The diary's peer group carries no listed comparators for this name; a well-known public name working in similar nucleic-acid and bioprocess reagent supply is Thermo Fisher Scientific.

Where does Maravai Lifesciences Holdings Inc sit in the AI build-out?

Maravai has no seat in Rubin or Halo, our AI build-out indices; it sits instead in the life-sciences tools sleeve of our wider universe, supplying reagents and nucleic-acid building blocks used in biologic and gene-therapy manufacturing rather than any layer of the compute stack. It carries no Closelook score and holds no seat in Rubin or Halo; its only recorded index membership is the Russell 1000, and the diary has not quoted or scored it so far.

What does this page show?

A live price chart with SMA overlays and drawing tools for MRVI, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe

then Biotechnology. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.